At a glance
- GHRP-2, also known as pralmorelin, is a synthetic ghrelin-receptor agonist that stimulates pituitary growth-hormone release. It is studied as a GHSR-pathway reference and is not a GHRH analogue.
- Pralmorelin has diagnostic-use history in Japan, but GHRP-2 is not an approved anti-aging or performance medicine in Canada or the United States. A research vial is not equivalent to a regulated diagnostic product.
- Use time-resolved GH sampling and a GHSR antagonist or receptor-negative control when receptor specificity matters.
- Measure ACTH, cortisol, prolactin, and appetite-related signals when off-target endocrine responses could affect interpretation.
What GHRP-2 is—and what the name does not establish
GHRP-2, also known as pralmorelin, is a synthetic ghrelin-receptor agonist that stimulates pituitary growth-hormone release. It is studied as a GHSR-pathway reference and is not a GHRH analogue.
GHRP-2 activates the growth-hormone secretagogue receptor, the same receptor family used by ghrelin. That signal can promote GH release and may also affect appetite, ACTH, cortisol, and prolactin depending on exposure and model.
Questions to settle before interpreting a result
A useful GHRP-2 study begins with material identity, a defined model, a relevant comparator, and an endpoint chosen before the result is known. Broad catalogue language cannot replace those controls.
- Use time-resolved GH sampling and a GHSR antagonist or receptor-negative control when receptor specificity matters.
- Measure ACTH, cortisol, prolactin, and appetite-related signals when off-target endocrine responses could affect interpretation.
- Compare with a GHRH analogue to separate ghrelin-receptor and GHRH-receptor routes to pituitary output.
How to read the GHRP-2 evidence
These evidence snapshots summarize the most important distinctions in the published record. They do not combine unlike models or turn an experimental signal into a human-use claim.
Human physiology
- Design
- GH-release activity is established in endocrine studies
- Finding
- Controlled human studies have shown acute GH responses to GHRP-2. Those studies support a secretagogue mechanism, not long-term claims about muscle, fat, recovery, or ageing.
- Read with care
- This is an interpretation boundary, not a claim that a specific outcome has been established in people.
Selectivity caution
- Design
- GH may not be the only hormonal response
- Finding
- GHRP-2 can influence ACTH/cortisol and prolactin in some settings. Measuring only GH can hide an endocrine effect relevant to the experiment.
- Read with care
- This is an interpretation boundary, not a claim that a specific outcome has been established in people.
Regulatory context
- Design
- Regional diagnostic use is not a general approval
- Finding
- Pralmorelin’s diagnostic role in Japan concerns a defined product and protocol. It does not establish anti-aging, performance, or clinical use for a catalogue vial.
- Read with care
- This is an interpretation boundary, not a claim that a specific outcome has been established in people.
What the evidence does not establish
Pralmorelin has diagnostic-use history in Japan, but GHRP-2 is not an approved anti-aging or performance medicine in Canada or the United States. A research vial is not equivalent to a regulated diagnostic product.
Mechanism, cell, animal, observational, and controlled human evidence answer different questions. A positive result at one level cannot be silently promoted to another, and evidence for a sponsor’s defined product does not establish equivalence for an independently sourced research material.
Keep the publication and the vial separate
A published paper identifies its own sequence or chemical identity, formulation, manufacturing context, analytical controls, exposure, and test system. Matching a familiar name on a label is not enough to show that a catalogue vial is the same study material.
For practical research planning, verify the lot-specific identity and documentation, then write the model, comparator, endpoint, and stopping criteria before testing. This guide does not provide preparation, dosing, injection, or human-use instructions.
Sources
Links lead to the paper, official registry, regulator page, or product label used for this guide. Registry records describe protocols and status; they are not treated as positive results.
- Effects of GHRP-2 and hexarelin on GH, prolactin, ACTH, and cortisol in humansPubMed-indexed human pharmacology study · 1997
Small acute endocrine study. Hormone-release signals do not establish durable body-composition, performance, recovery, or safety outcomes.
- Think twice before injecting peptides bought online: unauthorized products can seriously harm youHealth Canada · 2026
Official Canadian advisory explaining that a research-use label does not establish authorization, safety, efficacy, or product quality for human use.
Vote for GHRP-2
This compound is not currently stocked. Add it to your five-choice catalogue ballot.